BusinessRhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)By Nasdaq OMXApr 9, 2018, 11:00 AM UTC
